Clinical Study

Delphinol® standardized maqui berry extract improves blood glucose and insulin levels in a dose-dependent manner.

Format: PDF file | Document type: Clinical Study | Promoted Content

This content is provided by Anklam Extrakt GmbH, and any views and opinions expressed do not necessarily reflect those of www.nutraingredients-asia.com

Delphinol® standardized maqui berry extract improves blood glucose and insulin levels in a dose-dependent manner.

Delphinol®​, delphinidin-rich maqui berry standardized extract positively influences levels of fasting and postprandial blood glucose, as well as insulin levels in pre-diabetic subjects.

In the current study, pure glucose absorption was explored in an open trial. The results show postprandial blood glucose levels were lowered with all tested doses of 60, 120 and 180 mg Delphinol®​ in a dose-dependent manner, due to a drop in fasting glucose levels. The blood glucose peaks shifted from 30 minutes under placebo to 60 minutes after pure glucose intake with Delphinol®​.

Insulin levels were also lowered in a direct way, the underlying mechanism of action could be hypothesized.  

Further studies to explore the mechanism of action are underway.

Download clinical study for more details   

Related resources from Anklam Extrakt GmbH

Show more

Supplier info centre